EP1667729A4 - Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 - Google Patents

Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Info

Publication number
EP1667729A4
EP1667729A4 EP04776088A EP04776088A EP1667729A4 EP 1667729 A4 EP1667729 A4 EP 1667729A4 EP 04776088 A EP04776088 A EP 04776088A EP 04776088 A EP04776088 A EP 04776088A EP 1667729 A4 EP1667729 A4 EP 1667729A4
Authority
EP
European Patent Office
Prior art keywords
transcription factors
combinatoryly
aptamere
phosphorodithioate
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04776088A
Other languages
German (de)
English (en)
Other versions
EP1667729A2 (fr
Inventor
David G Gorenstein
Bruce A Luxon
Norbert Herzog
Judith F Aronson
David Beasley
Allan Barret
Robert E Shope
Xian Bin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP1667729A2 publication Critical patent/EP1667729A2/fr
Publication of EP1667729A4 publication Critical patent/EP1667729A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition et des procédés de fabrication et d'utilisation d'une banque combinatoire pour identifier les thioaptamères modifiés qui se lient à des facteurs de transcription tels que IL-6, NF-λB, AP-1 et analogue, et agissent sur la réponse immunitaire d'un animal hôte. L'invention concerne aussi une composition et des méthodes de traitement d'infections virales, ainsi que des vaccins et des adjuvants vaccinaux qui modifient les réponses immunitaires de l'hôte.
EP04776088A 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 Withdrawn EP1667729A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47288803P 2003-05-23 2003-05-23
PCT/US2004/016246 WO2005018537A2 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Publications (2)

Publication Number Publication Date
EP1667729A2 EP1667729A2 (fr) 2006-06-14
EP1667729A4 true EP1667729A4 (fr) 2007-10-17

Family

ID=34215796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04776088A Withdrawn EP1667729A4 (fr) 2003-05-23 2004-05-20 Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1

Country Status (3)

Country Link
EP (1) EP1667729A4 (fr)
CA (1) CA2526853A1 (fr)
WO (1) WO2005018537A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1635765B1 (fr) * 2003-05-23 2013-07-17 Board Of Regents, The University Of Texas System Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
EP1877069A2 (fr) 2005-05-04 2008-01-16 Noxxon Pharma AG Nouvelle utilisation de spiegelmers
BRPI1011269A2 (pt) * 2009-05-05 2016-09-27 Altermune Technologies Llc imunidade quimicamente programável
CA2902186C (fr) * 2013-03-14 2023-04-11 Somalogic, Inc. Aptameres se liant a l'il-6 et leur utilisation pour traiter ou diagnostiquer les pathologies associees a l'il-6

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026260A2 (fr) * 2002-09-17 2004-04-01 Archemix Corp. Aptameres vih prophylactiques et therapeutiques
WO2005003291A2 (fr) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
WO2005032455A2 (fr) * 2003-05-23 2005-04-14 Board Of Regents Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
WO2005037053A2 (fr) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026204A1 (fr) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
EP0855184A1 (fr) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
US6725526B2 (en) * 2002-01-14 2004-04-27 Hitachi Global Storage Technologies Netherlands B.V. Method of forming microsuspension assemblies for direct access storage devices

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026260A2 (fr) * 2002-09-17 2004-04-01 Archemix Corp. Aptameres vih prophylactiques et therapeutiques
WO2005003291A2 (fr) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
WO2005032455A2 (fr) * 2003-05-23 2005-04-14 Board Of Regents Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
WO2005037053A2 (fr) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KING DAVID J ET AL: "COMBINATORIAL SELECTION AND BINDING OF PHOSPHOROTHIOATE APTAMERS TARGETING HUMAN NF-KAPPA B RELA(P65) AND P50", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 41, no. 30, 30 July 2002 (2002-07-30), pages 9696 - 9706, XP009084286, ISSN: 0006-2960 *

Also Published As

Publication number Publication date
CA2526853A1 (fr) 2005-03-03
WO2005018537A3 (fr) 2005-05-26
EP1667729A2 (fr) 2006-06-14
WO2005018537A2 (fr) 2005-03-03

Similar Documents

Publication Publication Date Title
WO2006091915A3 (fr) Oligonucleotides immunostimulateurs
WO2004016805A3 (fr) Acides nucléiques immunostimulants
ATE426412T1 (de) Adjuvante influenza-vakzine
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ZA202207790B (en) Pharmaceutical composition and use thereof
WO2005079506A3 (fr) Procede d'activation de reponse immunitaire systemique au moyen de complexes d'acides nucleiques/lipides
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2005032455A8 (fr) Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
EP2601969A3 (fr) Formulations de vaccin contre un norovirus
MY125202A (en) Vaccine
NO20031646L (no) Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
NO20052828D0 (no) Polysakkaridvaksine for stafylokokkinfeksjoner
WO2006065553A3 (fr) Vaccins glycoconjugues contenant un peptidoglycane
DE60036698D1 (de) Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
EP4007600A4 (fr) Compositions de vaccin et méthodes de sélection d'antigènes
WO2002045742A3 (fr) Compositions immunogeniques d'acide lipoteichoique et procedes de preparation et d'utilisation associes
EP1660636A4 (fr) Vaccins anticancer
EP1667729A4 (fr) Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1
ATE402158T1 (de) Flavonoid-derivat
WO2005021033A3 (fr) Vaccin
ATE359815T1 (de) Streptococcus-phocae-vakzine
TNSN05052A1 (en) Immunostimulatory nucleic acids
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101AFI20070626BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070917

17Q First examination report despatched

Effective date: 20090130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090610